Article Figures & Data
Figures
- Figure 1
Immunogram of patient IMF-16. WBC and ALC are graphed in ×103/mm3 units; NY-ESO-1 titers are graphed in log10 as an inverse titer.
- Figure 2
Radiographic images of target lesions of patient IMF-16. Representative computer tomography (CT) images of IMF-16 demonstrating complete response in right lung lesions, progressive disease in right external iliac lymph nodes, and essentially stable subcarinal lymph nodes.
- Figure 3
CD4+ CD25+ and CD4+ FOXP3+ Tregs in peripheral blood and progressive right inguinal lymph node in patient IMF-16. CD4+ cells from the tumor tissue and from PBMCs were analyzed by flow cytometry and immunohistological staining for CD25 and FOXP3 expression. (A) Representative dot plots. (B) Compiled data. (C) CD4 immunohistochemical staining (clone BC/1F6). (D) FOXP3 immunohistochemical staining (clone 236A/E7).
- Figure 4
NY-ESO-1 antigen-specific CD8+ IFN-γ+ and CD4+ IFN-γ+ responses. The IFN-γ gate was set based on a negative control (alone) sample and applied across other samples (+NY-ESO-1). (A) Representative dot plots. (B) Compiled data. (C) MHC class I immunohistochemical staining (clone A4). (D) HLA-DR immunohistochemical staining (clone YE2/36HLK).
- Figure 5
Cancer/testis antigen expression on a progressive lymph node with tumor. Immunohistochemical staining of a lymph node metastasis for several cancer/testis antigens. Extensive immunoreactivity was seen with monoclonal antibodies (A) MA454 (to MAGE-A1), (B) M3H67 (to several MAGE-A antigens), (C) CT10-5 (to CT10/MAGE-C2), (D) E978 (to NY-ESO-1), (E) CT7-33 (to CT7/MAGE-C1), and (F) #26 (to GAGE).
Volume 10, Issue 1
